March 14, 2022
VERAXA Biotech GmbH Appoints Dr. Lars Hufnagel to Chief Technical Officer
Dr. Lars Hufnagel has been appointed Chief Technical Officer (CTO) of VERAXA Biotech, based in Heidelberg, Germany.
Pharmaceuticals, Biotechnology and Life Sciences
Author: Dino Mustafić
March 14, 2022
AYOXXA Receives Fresh Capital for Commercial Growth in Europe, US and Asia Led by Prosnav Capital
AYOXXA Biosystems GmbH has announced the successful closing of a financing round which will provide runway for the coming 3 – 5 years. The round was led by Hong Kong-based strategic investor, Prosnav Capital, who will provide AYOXXA access to the Asian market with a broad regional network. Besides Prosnav, a group of existing shareholders participated in the financing.
March 14, 2022
Arctoris and Evariste Technologies Partner to Identify Novel Small Molecule Inhibitors for the Treatment of Lung Cancer
Arctoris and Evariste Technologies have formed a joint venture to identify novel small molecule kinase inhibitors for treatment of patients…
March 14, 2022
BMS’s and Nektar Therapeutics’s Join Study of Bempegaldesleukin in Combination with Opdivo for Treatment of Melanoma Failed to Meet Expectations
Bristol Myers Squibb (NYSE: BMY) and Nektar Therapeutics (NASDAQ: NKTR) have announced an update following the first analysis of the…
March 14, 2022
Novartis announces New Data on Zolgensma for Treating SMA
Novartis has announced new data that reinforce the transformational benefit of Zolgensma (onasemnogene abeparvovec), an essential one-time treatment for spinal muscular atrophy (SMA).
March 14, 2022
SeaBeLife Receives Close to €1.4M Deep Tech Financing From Bpifrance
SeaBeLife has received €1.37M ($1.49M) in financing from Bpifrance. This financing, which has been granted in connection with the French government’s ‘Deeptech Plan’, will contribute to research into first-in-class drug candidates for the treatment of acute liver, kidney, heart and brain disease, SeaBeLife said in its press release.
March 14, 2022
Sanofi’s Phase 2 Clinical Trial for Breast Cancer Drug Fails to Meet Primary Endpoint
The Phase 2 AMEERA-3 clinical trial evaluating amcenestrant, an investigational optimized oral selective estrogen receptor degrader (SERD), did not meet…
March 11, 2022
Valneva Provides Regulatory Update on its COVID-19 Vaccine Candidate
Valneva SE has provided an update on the regulatory review of its inactivated, COVID-19 vaccine candidate, VLA2001, by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA).
March 11, 2022
Sixteenth Annual BIO-Europe Spring Digital to Bring Together Over 2,000 Life Science Leaders
The 16th annual BIO-Europe Spring global life sciences partnering event will be held March 28–31, 2022 in a fully digital…
March 10, 2022
Exscientia and University of Oxford Launch “Xcellomics” Program to Expedite Early-Stage Academic Research and Translate Novel Biology Into Future Drug Discovery
Exscientia and the University of Oxford Target Discovery Institute (Oxford TDI) have announced the formation of Xcellomics – a program designed to source cellular functional assays from the global academic community to develop novel screens and identify targets and therapeutic candidates for unmet medical needs.